Two phase I studies of PTI-188, a radiolabeled murine antimelanin antibody, in patients with metastatic melanoma (MM).

8555 Background: Two completed single-dose Phase I studies explored the feasibility of treating MM by targeting melanin with a 188-Rhenium-labeled IgM mAb (PTI-188) to deliver high energy β radiati...